Medline Inc. filed a Form S-1 registration statement with the SEC on November 16, 2026, covering a secondary offering of 60,000,000 shares of Class A common stock by selling stockholders, with no proceeds going to the company.
Key Highlights
- 60 million shares offered: All shares are being sold by selling stockholders; Medline Inc. will not receive any proceeds from the offering.
- Underwriter option: The underwriters have the option to purchase up to an additional 9,000,000 shares from the selling stockholders within 30 days of the prospectus date.
- Concurrent repurchase: Medline Inc. and Medline Holdings have agreed to repurchase an aggregate of $200 million of shares of Class A common stock and Common Units directly from selling stockholders in a private, non-underwritten transaction.
- Assumed repurchase price: At an assumed purchase price of $39.47 per equity interest, the aggregate number of shares of Class A common stock and Common Units repurchased would be 5,067,128.
- Last closing price: On November 13, 2026, the closing sales price of Class A common stock as reported on Nasdaq was $39.47 per share.
- Exchange listing: Class A common stock is listed on NASDAQ:MDLN under the Nasdaq Global Select Market.
Medline's Secondary Offering and $200 Million Repurchase Details
According to the filing, Medline Inc. (NASDAQ:MDLN), a Delaware-incorporated company headquartered at 3 Lakes Drive, Northfield, Illinois, submitted a Form S-1 registration statement on November 16, 2026. The registration covers 60,000,000 shares of Class A common stock being offered entirely by selling stockholders. The company disclosed that it will not receive any proceeds from the sale of shares in this offering. Prior to the consummation of the offering, certain selling stockholders will exchange Common Units for shares of Class A common stock to be sold by them, according to the filing.
The filing also describes a concurrent repurchase arrangement. The company and Medline Holdings have agreed to repurchase an aggregate of $200 million of shares of Class A common stock and Common Units directly from the selling stockholders in what the filing characterizes as "a private, non-underwritten transaction" at a price per equity interest equal to the price paid by the underwriters in the offering. At the assumed purchase price of $39.47 per equity interest, that would result in repurchase of 5,067,128 shares and Common Units in aggregate. The filing states that to the extent Common Units are repurchased, the corresponding shares of Class B common stock will be transferred to Medline Inc. for no additional consideration and then cancelled and retired.
The filing notes that "the Repurchase is expected to close concurrently with the offering and is conditioned upon the closing of this offering," but that "the closing of this offering is not conditioned upon the closing of the Repurchase." The prospectus identifies Goldman Sachs and Co. LLC, Morgan Stanley, BofA Securities, and J.P. Morgan as global coordinators and joint bookrunning managers, with Blackstone Capital Markets and Carlyle listed as co-managers. James Boyle is identified as Chief Executive Officer and Alex Liberman as Chief Legal Officer of Medline Inc.
What Was Disclosed
Medline Inc. filed a preliminary S-1 prospectus on November 16, 2026, registering 60,000,000 shares of Class A common stock for sale by selling stockholders, alongside a concurrent $200 million repurchase by the company and Medline Holdings from those same selling stockholders.



Please wait processing your request...